Table 1.
Patient and healthy donor characteristics.
| MDS cohort n = 98 | Healthy control n = 28 | p-value | |
|---|---|---|---|
| Population data | |||
| Age, mean (range) | 70.8 (44–86) | 71.4 (36–84) | 0.78* |
| Sex | |||
| Male | 65 | 14 | 0.13# |
| Female | 33 | 14 | |
| WHO 2016 | |||
| aCML | 2 | ||
| CMML | 3 | ||
| del5q-MDS | 15 | ||
| MDS-MLD | 33 | ||
| MDS/MPN-U | 2 | ||
| MDS-EB1 | 12 | ||
| MDS-EB2 | 12 | ||
| MDS-MLD-RS | 9 | ||
| MDS-MLD-RS-T | 1 | ||
| MDS-U | 3 | ||
| sAML | 4 | ||
| tMN | 2 | ||
| Bone marrow cytogenetics | |||
| Normal | 52 | ||
| Complex aberrant | 14 | ||
| del5q | 17 | ||
| del7q | 1 | ||
| del9 | 1 | ||
| trisomy 8 | 4 | ||
| Other | 4 | ||
| n.a. | 5 | ||
| Treatment prior to MSC sampling | |||
| ESA | 14 | ||
| Lenalidomide | 14 | ||
| Post cytotoxic therapy | 3 | ||
| Post HMA | 16 | ||
| No treatment | 51 | ||
ESA erythropoiesis stimulating agents, HMA hypomethylating agents.
*Two-sided students t test.
#Two-sided Fisher exact test.